Attorney John J. Driscoll Files Lawsuit Against Manufacturer of Actos Diabetes Drug
The Driscoll Firm, P.C., has filed the second lawsuit in a month in Illinois state court that seeks compensation for plaintiffs who allege that they developed bladder and urinary problems after taking the Actos diabetes drug.
St. Louis, MO (PRWEB) April 27, 2013
The companies behind the Actos diabetes drug knowingly manufactured and distributed a product that could allegedly cause serious bladder and urinary problems — including cancer — without warning consumers of those risks, according to the allegations in a new lawsuit filed in St. Clair County Circuit Court in Illinois by nationally recognized drug injury lawyer John J. Driscoll.
The Driscoll Firm, P.C., filed the lawsuit (Case No. 13-L-184) on April 5, two weeks after the law firm filed a complaint in St. Clair County Circuit Court (Case No. 13-L-153) alleging similar claims against the same group of defendants.
The defendants, who are alleged to have manufactured, designed and distributed Actos, are Takeda Pharmaceuticals North America Inc., Takeda Global Research & Development Center Inc., Takeda Pharmaceuticals LLC, Takeda San Diego Inc. and Takeda Pharmaceuticals International Inc.
The most recent lawsuit claims that the plaintiffs developed urinary and bladder issues, including bladder cancer, after they had consumed Actos (or pioglitazone). The drug also is sold under the names Actoplus Met, Actoplus Met XR and Duetact, the complaint states.
According to the lawsuit, the plaintiffs´ illnesses have allegedly forced them to pay undue medical costs and experience physical pain, mental anguish and a loss of enjoyment of life.
Both Actos lawsuits have been reported on by The Madison-St. Clair Record legal journal.
The U.S. Food and Drug Administration (FDA) has approved Actos for use in improving control of blood sugar in adults with Type 2 diabetes mellitus.
However, in June 2011, the FDA issued a safety communication, informing the public that use of Actos for more than one year “may be associated with an increased risk of bladder cancer.” The FDA also mandated a labeling change to include information about this risk.
Driscoll urged Actos users to be on alert for symptoms of bladder cancer, which the FDA identifies as blood or red color in urine, the urgent need to urinate, pain while urinating and pain in the back or lower abdomen.
He noted that the FDA has recommended that doctors refrain from prescribing Actos to patients with active bladder cancer or a prior history of the disease.
Driscoll said that concerned patients and family members should visit the law firm´s website, SettlementHelpers.com, to view the latest legal and medical updates about Actos.
About The Driscoll Firm, P.C.
The Driscoll Firm, P.C., is dedicated to fighting for the rights of people and families injured by the wrongful acts of individuals and companies. The firm is currently investigating product liability claims involving defective drugs and dangerous medical devices. The Driscoll Firm, P.C., is based at 211 N. Broadway, 40th Floor, St. Louis, MO, 63102, and serves clients nationwide. To learn more, call (800) 305-9800 or use the firm´s online contact form. All initial consultations are free and confidential.
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebactos-bladder-cancer/new-lawsuit-filed/prweb10677852.htm